drugset
drugset / Trial / NCT04148937

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

NCT04148937 ↗

Phase 1 Completed 52 enrolled Eli Lilly and Company Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.

Timeline

Start
2020-01-16
Primary completion
2021-05-12
Completion
2022-06-20

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3475070 Small molecule 150 mg Oral
Subject LY3475070 Small molecule 300 mg Oral
Subject LY3475070 Small molecule 600 mg Oral
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

No indication recorded.